Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Genitourinary Syndrome of Menopause: early-phase trial registry

3 of 7 indexed Genitourinary Syndrome of Menopause trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 3 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Genitourinary Syndrome of Menopause: 7 US clinical trials tracked, 3 recruiting.

Genitourinary Syndrome of Menopause is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Stratpharma, running 2 of these trials.

Enrollment posture brief

Registry condition genitourinary-syndrome-of-menopause

OPEN 3 | RECR 43% | LATE 0 | EARLY 1 | RANK #2497 | SPON 2

Nearest open-share peer: Adrenoleukodystrophy (43% recruiting · 7 trials)

ACL Tear71.4%ACL57.1%Genitourinary Syndrome o (th…43%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Genitourinary Syndrome of Menopause

Genitourinary Syndrome of Menopause lists 3 open slots (43% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Genitourinary Syndrome of Menopause on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Genitourinary Syndrome of Menopause is recruiting below its size-band peers.

    3 of 7 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Genitourinary Syndrome of Menopause research.

    Stratpharma accounts for 2 of 7 trials (28.6%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Genitourinary Syndrome of Menopause trials plan to enrol fewer than 100 people.

    Median target enrolment is 50 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.

  4. Genitourinary Syndrome of Menopause research is mostly interventional.

    7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Genitourinary Syndrome of Menopause records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

MonaLisa Touch Device
1 trials
Platelet-rich plasma (PRP) Biological
1 trials
Injection of saline Procedure
1 trials
Injection of platelet-rich plasma Procedure
1 trials
CO2 laser Device
1 trials
Estrace 0.01% Vaginal Cream Drug
1 trials
StrataMGT Device
1 trials
7-0940 Device
1 trials

US sites by state

Facility locations filed on Genitourinary Syndrome of Menopause trials. A trial with sites in several states counts in each.

California 4 trials
Florida 3 trials
Georgia 2 trials
Texas 1 trials
Tennessee 1 trials
South Carolina 1 trials
Nevada 1 trials
North Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Genitourinary Syndrome of Menopause page

7 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 3 Genitourinary Syndrome of Menopause trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Stratpharma sponsors the most Genitourinary Syndrome of Menopause trials on record, review their full trial history before evaluating a specific study. See Stratpharma's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Genitourinary Syndrome of Menopause condition card totals 7 registered trials; most-linked intervention MonaLisa Touch; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.